Feb’24: Vibcare Pharmaceuticals, a leading pharmaceutical company dedicated to healthcare excellence, reaffirms its commitment to quality and safety through proactive compliance with the Union Health Ministry's recently revised Schedule M guidelines.
The government's announcement of significant revisions to the Schedule M guidelines marked the beginning of a fresh phase of pharmaceutical manufacturing in India. Effective from December 28, 2023, these revisions mandate stringent measures to ensure pharmaceutical product safety and quality standards, as well as transparency and accountability throughout the industry.
Vibcare Pharmaceuticals welcomes these modifications, seeing them as an essential step toward boosting industry standards and encouraging the development of safer and more effective medicines. Vibcare Pharmaceuticals, with a strong commitment to compliance, has quickly implemented measures to align with the new guidelines, ensuring that its products comply with and exceed regulatory requirements.
Key highlights of Vibcare Pharmaceuticals' compliance with the revised Schedule M guidelines:
Stringent Reporting Procedures:Vibcare Pharmaceuticals has developed strong reporting procedures to promptly notify the licensing authority of any drug recalls, product defects, deterioration, or faulty production in strict compliance with the revised guidelines.
Emphasis on Good Manufacturing Practices (GMP): The company places a high value on GMP standards, ensuring that product quality matches its intended application and meets licensing requirements.
Stability Testing and Global Standards:Vibcare Pharmaceuticals examines drug substances for stability under recommended climate conditions in accordance with global standards established by reputable organizations such as the World Health Organization (WHO).
Pharmacovigilance System: The company has established a comprehensive system to collect, process, and send out reports on adverse drug reactions, maintaining continuous monitoring and reporting of potential risks associated with its products.
Seamless Transition:Vibcare Pharmaceuticals has taken advantage of the government's transition period, allowing it to adapt to the new guidelines without jeopardizing its ongoing operations.
Vibcare Pharmaceuticals remains focused on maintaining the highest quality and safety standards in pharmaceutical manufacturing, ensuring its products meet evolving regulatory requirements and global best practices.
For more information on Vibcare Pharmaceuticals and the company's compliance to the revised Schedule M guidelines, please visit https://vibcare.co.in/schedule-m-guidelines-2024. For more information about the company, please visit https://vibcare.co.in/. You can also follow them onTwitterand Facebook.

About the Company:
Vibcare Pharma Pvt. Ltd., an ISO-certified firm, enjoys the confidence of numerous clients. Leveraging more than four decades of involvement in the pharmaceutical sector, they cater to over a thousand Pharma Franchise enterprises. Additionally, they present dependable provisions such as PCD Pharma and Third Party Contract Manufacturing. The company, Vibcare Pharma Pvt. Ltd., furnishes comprehensive and unified contract manufacturing and developmental solutions to the clientele, coupled with exceptional customer support services.
Contact Details: Vibcare Pharma Pvt. Ltd.
Address: Plot no 4, HSIIDC I.T. Park, Sector 22, Panchkula, Haryana, India
Phone Number: 9888988858
Company Email ID: [email protected]